百奥赛图-B(02315)午后涨超6%，截至发稿，涨6.33%，报52.95港元，成交额3402.99万港元。 智通财经APP获悉，百奥赛图-B(02315)午后涨超6%，截至发稿，涨6.33%，报52.95港元，成交额 3402.99万港元。 消息面上，百奥赛图近期发布2025年度业绩预告，预计全年实现营收约13.69亿元至13.89亿元，同比增 幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，同比大幅增长384.26%至 443.88%。 国联民生证券发布研报称，受益于模式动物及临床前CRO业务的创新优势、"千鼠万抗"计划支持下的抗 体平台优势，百奥赛图2025年业绩表现亮眼。该行指出，2025年以来，公司与多家国内外头部药企达成 对外授权，并有多条管线获得IND批准，随着授权管线的推进，公司有望获得里程碑付款等收入，进一 步打开增长天花板。 ...

Core Viewpoint - BaiOScitech-B (02315.HK) experienced a significant increase in stock price, rising over 6% in the afternoon trading session on February 11, reaching a price of 52.95 HKD with a trading volume of 34.03 million HKD [1] Summary by Category - **Stock Performance** - The stock price of BaiOScitech-B rose by 6.33% to 52.95 HKD [1] - The trading volume was reported at 34.03 million HKD [1]

Core Viewpoint - Baosai Tu-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Group 1: Financial Performance - The company forecasts a revenue of approximately 1.369 billion to 1.389 billion yuan for 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - Expected net profit attributable to shareholders is projected to be between 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Group 2: Business Drivers - Guolian Minsheng Securities highlights the company's innovative advantages in model animals and preclinical CRO business, as well as the strengths of its antibody platform supported by the "Thousand Mice, Ten Thousand Antibodies" initiative [1] - Since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]

国联民生证券发布研报称，受益于模式动物及临床前CRO业务的创新优势、"千鼠万抗"计划支持下的抗 体平台优势，百奥赛图2025年业绩表现亮眼。该行指出，2025年以来，公司与多家国内外头部药企达成 对外授权，并有多条管线获得IND批准，随着授权管线的推进，公司有望获得里程碑付款等收入，进一 步打开增长天花板。 消息面上，百奥赛图近期发布2025年度业绩预告，预计全年实现营收约13.69亿元至13.89亿元，同比增 幅为39.61%到41.65%；预计实现归母净利润约为1.62亿元-1.82亿元，同比大幅增长384.26%至 443.88%。 智通财经APP获悉，百奥赛图-B(02315)午后涨超6%，截至发稿，涨6.33%，报52.95港元，成交额 3402.99万港元。 ...

Group 1 - The company, BaiAoSaiTu, has led and promoted the on-demand model of humanized mice, catering to the research and development needs of numerous overseas pharmaceutical clients [1] - As a result of this strategy, the proportion of overseas revenue has been increasing year by year [1]

Core Viewpoint - BaiO Saite's stock price increased by 3.67% on February 5, with a trading volume of 180 million yuan and a market capitalization of 32.548 billion yuan [1] Group 1: Company Overview - BaiO Saite (Beijing) Pharmaceutical Technology Co., Ltd. was established on November 13, 2009, and is listed on December 10, 2025 [7] - The company primarily engages in drug development and preclinical research, operating through five divisions: gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development [7][3] - The company is located in the Daxing District of Beijing, within the Zhongguancun Science Park [7] Group 2: Business Performance - As of the 2024 annual report, overseas revenue accounted for 67.94% of total revenue, benefiting from the depreciation of the yuan [3] - The company is involved in providing customized gene editing services based on animals and cells, preclinical pharmacology services for drug efficacy and toxicity evaluation, breeding and selling model animals, identifying potential therapeutic antibodies, and developing innovative drugs focused on oncology and autoimmune diseases [7] Group 3: Market Activity - The stock has seen a net inflow of 14.4873 million yuan today, with a continuous increase in main funds for three days [4] - The average trading cost of the stock is 67.99 yuan, with recent accumulation activity noted, although the strength of accumulation is weak [6] - The stock price is approaching a resistance level of 74.29 yuan, indicating potential for a price correction if this level is not surpassed [6]

百奥赛图（北京）医药科技股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688796 证券简称：百奥赛图 百奥赛图（北京）医药科技股份有限公司 2026 年第一次临时股东会 会议资料 2026 年 2 月 百奥赛图（北京）医药科技股份有限公司 2026 年第一次临时股东会会议资料 | | | | 2026 | 年第一次临时股东会会议须知 1 | | --- | --- | | 2026 | 年第一次临时股东会会议议程 3 | | 2026 | 年第一次临时股东会会议议案 5 | | | 议案一：《关于补选公司第二届董事会非执行董事的议案》 5 | 百奥赛图（北京）医药科技股份有限公司 2026 年第一次临时股东会会议资料 百奥赛图（北京）医药科技股份有限公司 2026 年第一次临时股东会会议须知 为维护广大投资者的合法权益，保障股东在本次股东会期间依法行使权利， 确保股东会的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》、中国证监会《上市公司股东会规 则》以及《百奥赛图（北京）医药科技股份有限公司章程》及《百奥赛图（北京） 医药科技股份有限公 ...

Core Viewpoint - Baosai Tu-B (02315) has seen a significant stock price increase of over 5%, currently trading at HKD 47.96, with a transaction volume of HKD 69.87 million. The company has released its revenue forecast for the fiscal year 2025, indicating substantial growth in both revenue and net profit compared to the previous year [1]. Financial Performance - The company expects to achieve revenue between RMB 1.369 billion and RMB 1.389 billion for the fiscal year 2025, representing an increase of RMB 389 million to RMB 408 million year-on-year, with a growth rate of 39.61% to 41.65% [1]. - The projected net profit attributable to shareholders is expected to be between RMB 162 million and RMB 182 million, reflecting an increase of RMB 129 million to RMB 149 million year-on-year, with a significant growth rate of 384.26% to 443.88% [1]. Business Development - Guolian Minsheng Securities (601456) highlights that the high demand for innovative animal models and preclinical CRO services is driving substantial revenue growth for the company. The firm notes that since 2025, the company has established external licensing agreements with several leading domestic and international pharmaceutical companies [1]. - The approval of multiple pipelines for IND (Investigational New Drug) is expected to further enhance the company's revenue potential through milestone payments as these licensed pipelines progress, thereby opening up additional growth opportunities [1].

Core Viewpoint - Baosai Tu-B (02315) has seen a significant stock price increase of over 5%, currently trading at HKD 47.96, with a transaction volume of HKD 69.87 million [1] Financial Performance - The company forecasts its 2025 annual revenue to be approximately HKD 1.369 billion to HKD 1.389 billion, representing an increase of HKD 389 million to HKD 408 million compared to the previous year, with a year-on-year growth rate of 39.61% to 41.65% [1] - The expected net profit attributable to shareholders is projected to be around HKD 162 million to HKD 182 million, an increase of HKD 129 million to HKD 149 million from the previous year, indicating a substantial year-on-year growth of 384.26% to 443.88% [1] Market Insights - Guolian Minsheng Securities believes that the high demand for innovative animal models and preclinical CRO services is driving significant revenue growth [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to generate milestone payments and further enhance growth potential [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 2. 股份分類 | 普通股 | 股份 ...